Technical Analysis for ALKS - Alkermes plc

Grade Last Price % Change Price Change
grade C 35.01 1.16% 0.40
ALKS closed up 1.16 percent on Tuesday, March 19, 2019, on approximately normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical ALKS trend table...

Date Alert Name Type % Chg
Mar 19 Bollinger Band Squeeze Range Contraction 0.00%
Mar 19 Narrow Range Bar Range Contraction 0.00%
Mar 19 NR7 Range Contraction 0.00%
Mar 19 Doji - Bearish? Reversal 0.00%
Mar 19 Stochastic Reached Overbought Strength 0.00%
Mar 19 BB Squeeze + Upper Band Touch Range Contraction 0.00%
Mar 19 Gapped Up Strength 0.00%
Mar 19 Overbought Stochastic Strength 0.00%
Mar 19 Up 3 Days in a Row Strength 0.00%
Mar 19 Upper Bollinger Band Touch Strength 0.00%

Older signals for ALKS ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Alkermes Public Limited Company, an integrated biopharmaceutical company, develops medicines that enhance patient outcomes. The company offers RISPERDAL CONSTA for schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia; AMPYRA/ FAMPYRA for the treatment of multiple sclerosis; BYDUREON for the treatment of type II diabetes; VIVITROL for alcohol and opioid dependence; TRICOR, LIPANTHYL, LIPIDIL, and SUPRALIP to lower cholesterol; ZANAFLEX for muscle spasticity; AVINZA for severe pain; EMEND for the treatment of nausea associated with chemotherapy and surgery; and FOCALIN XR and RITALIN LA for attention deficit and hyperactivity disorder. Its products also include MEGACE ES for the treatment of cachexia associated with AIDS; LUVOX CR for obsessive-compulsive disorder; RAPAMUNE for the prevention of renal transplant rejection; NAPRELAN for various mild to moderate pain indications; VERAPAMIL SR, VERELAN, VERELAN PM, VERAPAMIL PM, VERECAPS, UNIVER, and AFE Ditab CR for hypertension; and DILZEM SR, DILZEM XL, DILTELAN, ACALIX CD, DINISOR, TILAZEM CR, and CARDIZEM CD for hypertension and/or angina. In addition, it develops ALKS 9070, which is in phase 3 study for the treatment of schizophrenia; ALKS 37 that is under phase 2b study for the treatment of opioid-induced constipation; ALKS 33, which has completed phase 2 study for modulation of brain opioid receptors; ALKS 5461 that is under phase 2 study for the treatment of depressive disorder, as well as under phase 1b study for the treatment of cocaine dependence; and ZOHYDRO for pain relief. The company serves pharmaceutical wholesalers, specialty pharmacies, and specialty distributors directly through its sales force. It has collaboration with Janssen Pharmaceutica N.V. for the development of RISPERDAL CONSTA. The company was founded in 1987 and is headquartered in Dublin, Ireland.
Chemistry Biopharmaceutical Pain Surgery Chemotherapy Organic Chemistry Schizophrenia Multiple Sclerosis Hypertension Morphinans Neurochemistry Nausea Ii Diabetes Depressive Disorder Obsessive Compulsive Disorder AIDS Hyperactivity Disorder Opioid Antagonists Pharmaceutical Wholesalers Treatment Of Multiple Sclerosis Angina Atypical Antipsychotics Opioid Induced Constipation Renal Transplant
Is ALKS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 61.21
52 Week Low 27.54
Average Volume 825,987
200-Day Moving Average 38.9249
50-Day Moving Average 32.9956
20-Day Moving Average 33.5145
10-Day Moving Average 33.369
Average True Range 1.1042
ADX 9.18
+DI 27.1369
-DI 17.0627
Chandelier Exit (Long, 3 ATRs ) 32.0374
Chandelier Exit (Short, 3 ATRs ) 34.9026
Upper Bollinger Band 35.0372
Lower Bollinger Band 31.9918
Percent B (%b) 0.99
BandWidth 9.086813
MACD Line 0.3461
MACD Signal Line 0.1956
MACD Histogram 0.1504
Fundamentals Value
Market Cap 5.38 Billion
Num Shares 154 Million
EPS -1.29
Price-to-Earnings (P/E) Ratio -27.14
Price-to-Sales 10.50
Price-to-Book 7.03
PEG Ratio -1145.21
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 35.80
Resistance 3 (R3) 35.82 35.59 35.67
Resistance 2 (R2) 35.59 35.39 35.57 35.62
Resistance 1 (R1) 35.30 35.26 35.44 35.27 35.58
Pivot Point 35.06 35.06 35.13 35.05 35.06
Support 1 (S1) 34.77 34.86 34.92 34.75 34.44
Support 2 (S2) 34.54 34.74 34.52 34.40
Support 3 (S3) 34.25 34.54 34.35
Support 4 (S4) 34.22